Requires the office of addiction services and supports to encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction.
Establishes the community chemical dependency services expansion program; provides funding for local governmental units for the provision of new and expanded chemical dependency services.
Relates to the distribution of educational materials regarding the misuse of and addiction to prescription drugs in counties with the most prevalent abuse of prescription opioids.
Provides that when informational cards or sheets about opioid antagonists are distributed, such information shall include information about fentanyl strips and their uses.
Requires that the siting, construction and establishment of methadone program facilities in cities with a population of one million or more be dispersed in the boroughs of such cities in proportion to the population of each such borough.
Establishes an intensive addiction recovery and mental health integrated services pilot program to support two three-year demonstration programs that provide intensive addiction and mental health integrated services to individuals with significant addiction and mental health issues who have had multiple and frequent treatment episodes.
Requires public institutions and buildings to be equipped with opioid antagonists; directs the commissioner of general services to promulgate regulations to address the appropriate number of opioid antagonists for such buildings based on the size or occupancy of the buildings, the training of personnel and use of opioid antagonists, and any other matter deemed necessary.
Requires that where a health care professional or professionals require the completion of an allergy checklist or form by the patient, prior to receiving care by such professional or professionals, the checklist or form shall also inquire about the opioid history of such patient.
Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agents approved by the federal food and drug administration.